Questionnaire

1. Clinical trials have shown that patients with diabetes and renal disease do not experience lower CV and all-cause death from tight glucose control (<7%) once they already have renal disease; therefore tighter glycaemic control is vital before nephropathy develops.

2. The use of SGLT-2 inhibitors at low eGFR (<45ml/min/1.73%) result in:

3. Patients with diabetes and DKD have a higher risk of hypoglycaemia because of:

4. In the early stages of DKD, insulin requirements are:

5. Patients with diabetes and mild-to-moderate DKD requiring insulin for glycaemic control have been shown to benefit from: